51 related articles for article (PubMed ID: 24618431)
21. Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.
Hayashi H; Kohno T; Ueno H; Hiraoka N; Kondo S; Saito M; Shimada Y; Ichikawa H; Kato M; Shibata T; Morizane C; Sakamoto Y; Shimada K; Komatsu Y; Sakamoto N; Okusaka T
Pancreas; 2017 Mar; 46(3):335-340. PubMed ID: 28099251
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenomics update in pancreatic cancer.
Puri A; Saif MW
JOP; 2014 Mar; 15(2):114-7. PubMed ID: 24618431
[TBL] [Abstract][Full Text] [Related]
23. [Genetic aspects of pancreatic cancer].
Grigor'eva IN; Efimova OV; Suvorova TS; Tov NL
Eksp Klin Gastroenterol; 2014; (10):70-6. PubMed ID: 25911935
[TBL] [Abstract][Full Text] [Related]
24. KRAS in pancreatic cancer.
Agarwal A; Saif MW
JOP; 2014 Jul; 15(4):303-5. PubMed ID: 25076326
[TBL] [Abstract][Full Text] [Related]
25. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications.
Hu HF; Ye Z; Qin Y; Xu XW; Yu XJ; Zhuo QF; Ji SR
Acta Pharmacol Sin; 2021 Nov; 42(11):1725-1741. PubMed ID: 33574569
[TBL] [Abstract][Full Text] [Related]
26. Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues.
Voutsadakis IA; Digklia A
Chin Clin Oncol; 2023 Feb; 12(1):2. PubMed ID: 36922358
[TBL] [Abstract][Full Text] [Related]
27. Phenotype and genotype of pancreatic cancer cell lines.
Deer EL; González-Hernández J; Coursen JD; Shea JE; Ngatia J; Scaife CL; Firpo MA; Mulvihill SJ
Pancreas; 2010 May; 39(4):425-35. PubMed ID: 20418756
[TBL] [Abstract][Full Text] [Related]
28. Evolution and dynamics of pancreatic cancer progression.
Yachida S; Iacobuzio-Donahue CA
Oncogene; 2013 Nov; 32(45):5253-60. PubMed ID: 23416985
[TBL] [Abstract][Full Text] [Related]
29. Genetics and Biology of Pancreatic Ductal Adenocarcinoma.
Dunne RF; Hezel AF
Hematol Oncol Clin North Am; 2015 Aug; 29(4):595-608. PubMed ID: 26226899
[TBL] [Abstract][Full Text] [Related]
30. [Kras oncogene and pancreatic cancer: thirty years after].
Bournet B; Dufresne M; Selves J; Torrisani J; Cordelier P; Buscail L
Med Sci (Paris); 2013 Nov; 29(11):991-7. PubMed ID: 24280502
[TBL] [Abstract][Full Text] [Related]
31. p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation.
Wang K; Baldwin GS; Nikfarjam M; He H
World J Gastroenterol; 2018 Sep; 24(33):3709-3723. PubMed ID: 30197477
[TBL] [Abstract][Full Text] [Related]
32. Pharmacogenetics in neuroendocrine tumors of the pancreas.
Rizvi SM; Wong J; Saif MW; Jia Y
JOP; 2014 Jul; 15(4):299-302. PubMed ID: 25076325
[TBL] [Abstract][Full Text] [Related]
33. Genetic landscape of pancreatic cancer: a narrative review.
Yakar DÖ; Bozkırlı BO; Ceyhan GO
Chin Clin Oncol; 2022 Feb; 11(1):5. PubMed ID: 35255694
[TBL] [Abstract][Full Text] [Related]
34. Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival.
Ulanja MB; Moody AE; Beutler BD; Antwi-Amoabeng D; Rahman GA; Alese OB
Oncotarget; 2022; 13():828-841. PubMed ID: 35720978
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenetics and Personalized Medicine in Pancreatic Cancer.
Hosseini Bereshneh A; Morshedi F; Hematyar M; Kaki A; Garshasbi M
Acta Med Iran; 2017 Mar; 55(3):194-199. PubMed ID: 28282719
[TBL] [Abstract][Full Text] [Related]
36. [Molecular predictors for the course of disease and individualized therapy in pancreatic cancer].
Damanakis AI; Gebauer F; Bruns CJ
Chirurg; 2020 Aug; 91(8):642-649. PubMed ID: 32405728
[TBL] [Abstract][Full Text] [Related]
37. Basic principles and technologies for deciphering the genetic map of cancer.
Voidonikolas G; Kreml SS; Chen C; Fisher WE; Brunicardi FC; Gibbs RA; Gingras MC
World J Surg; 2009 Apr; 33(4):615-29. PubMed ID: 19115029
[TBL] [Abstract][Full Text] [Related]
38. Mutations of p53 associated with pancreatic cancer and therapeutic implications.
Voutsadakis IA
Ann Hepatobiliary Pancreat Surg; 2021 Aug; 25(3):315-327. PubMed ID: 34402431
[TBL] [Abstract][Full Text] [Related]
39. Molecular landscape of pancreatic cancer: implications for current clinical trials.
Heestand GM; Kurzrock R
Oncotarget; 2015 Mar; 6(7):4553-61. PubMed ID: 25714017
[TBL] [Abstract][Full Text] [Related]
40. Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development.
Dreyer SB; Chang DK; Bailey P; Biankin AV
Clin Cancer Res; 2017 Apr; 23(7):1638-1646. PubMed ID: 28373362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
